Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection

Marguerite L. Monogue, David P. Nicolau
Marguerite L. Monogue
aCenter for Anti-infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David P. Nicolau
aCenter for Anti-infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA
bDivision of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01329-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.

TEXT

Urinary tract infections (UTIs) are one of the most common types of community-acquired and nosocomial infections, impacting 150 million people per year globally (1). Escherichia coli is the leading cause of UTIs, and often displays resistance to currently available antibiotics due to the production of various enzymes, such as extended-spectrum β-lactamases (ESBLs) (1). ESBLs are enzymes produced by Gram-negative bacteria, namely, E. coli, and are responsible for the resistance against penicillins, cephalosporins, and aztreonam (2). Carbapenems, such as ertapenem, are standard for the treatment of infections caused by ESBL-producing organisms, although the potential clinical utility of extended-spectrum cephalosporins, notably cefepime, has yet to be clearly defined. Herein, we used humanized exposures of cefepime, 2 g every 8 h (q8h) (0.5-h infusion), ertapenem, 1 g every 24 h (q24h), and levofloxacin, 500 mg q24h, against uropathogenic ESBL- and non-ESBL-producing E. coli and assessed antimicrobial efficacy after 24 and 48 h of therapy in a neutropenic murine complicated UTI (cUTI) model.

Commercially available cefepime 1g (lot no. 106014C), ertapenem 1g (lot no. m027105), and levofloxacin 500 mg (lot no. CLF150003) vials were acquired from Cardinal Health, Inc. Vials were reconstituted according to the package insert and further diluted with 0.9% normal saline solution (Hospira, Inc., Lake Forest, IL). Doses were administered as 0.2-ml subcutaneous injections to achieve humanized exposures of 2 g cefepime q8h (0.5-h infusion), 1 g ertapenem q24h, and 500 mg levofloxacin q24h, as previously described (3–5).

Two clinical uropathogenic E. coli isolates (EC 429, ESBL; EC 430, non-ESBL) were used in this study. The MICs of cefepime, ertapenem, and levofloxacin were determined in triplicates by broth microdilution as described by the Clinical and Laboratory Standards Institute guidelines (6).

Pathogen-free female ICR mice weighing 20 to 22 g were obtained from Envigo RMS, Inc. (Indianapolis, IN). The protocol was reviewed and approved by the Institutional Animal Care and Use Committee at Hartford Hospital. Mice were rendered transiently neutropenic by injecting cyclophosphamide intraperitoneally at a dose of 150 mg/kg of body weight 4 days before and 100 mg/kg 1 day before inoculation. Uranyl nitrate 5 mg/kg was administered 3 days prior to inoculation to produce a controlled degree of renal impairment.

A previously published direct inoculation model was used to establish UTIs in mice (7, 8). Two transfers of the bacterial isolate were performed on Trypticase soy agar with 5% sheep blood (Becton, Dickinson & Co., Sparks, MD) and placed into an incubator at 37°C for approximately 24 h. A bacterial suspension of approximately 107 CFU/ml was prepared in sterile saline. Anesthesia was established with a 0.2-ml intraperitoneal dose of ketamine 100 mg/kg of body weight, xylazine 10 mg/kg, and acepromazine 3 mg/kg. The areas over each kidney (flanks) were shaved and prepped for surgical incisions. Surgical preps proceeded as follows: surgical scrub, blot with sterile gauze, surgical solution, and blot with sterile gauze. Incisions were made in the skin on each flank to visualize the kidneys. A volume of 0.05 ml of the bacterial isolate was injected directly into each kidney. The skin was closed with 4.0 Vicryl suture material with an RB-1 needle. Mice were kept in a warm oxygen-enriched environment and monitored during the postoperative period until they fully recovered from anesthesia (3 h). Control animals received sterile normal saline of the same volume with the same route and schedule as the most frequently dosed drug regimen. For each isolate tested, 3 untreated mice were used as 0-h controls and 3 additional mice (receiving normal saline) were used as 24- and 48-h controls each. All regimens were studied in groups of 3 mice over 24- and 48-h treatment periods for each bacterial isolate. After inoculation, one group for each bacterial isolate was euthanized by CO2 exposure followed by cervical dislocation. At 24 and 48 h after the initiation of dosing, the treatment and control groups were euthanized. After sacrificing, the kidneys were removed and homogenized in normal saline. Serial dilutions were plated on an appropriate agar medium for CFU determination.

Table 1 presents the phenotypic profile of cefepime, ertapenem, and levofloxacin for EC 429 and EC 430 isolates. EC 429, an ESBL producer, was resistant to cefepime and levofloxacin but susceptible to ertapenem. EC 430 was pansusceptible to all three agents.

View this table:
  • View inline
  • View popup
TABLE 1

MICs of EC 429 and EC 430

The initial bacterial density in the kidneys 3 h postinoculation (0 h) was 5.2 ± 0.03 log10 CFU/ml. Both test organisms displayed sustained growth over the 48-h study period in the kidneys of control animals, reaching 9.7 ± 0.1 log10 CFU/ml. Figure 1 illustrates the antibacterial efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against EC 429 and EC 430 after 24 and 48 h of treatment. Consistent with their phenotypic profiles, the cefepime and levofloxacin regimens demonstrated poor microbiologic responses against EC 429, whereas ertapenem exhibited >2 log kill over the 48-h treatment period. Based on the pansusceptibility of EC 430, humanized exposures of cefepime, ertapenem, and levofloxacin resulted in >2 log kill over the 48-h treatment period for all regimens.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Efficacy (mean change in log10 CFU from 0-h control) of human simulated treatment with cefepime 2 g q8h (0.5-h infusion), ertapenem 1 g q24h, and levofloxacin 500 mg q24h against EC 429 (left) and EC 430 (right) after 24 and 48 h.

The use of noncarbapenem antimicrobials for the treatment of ESBL UTIs remains a clinical controversy. Herein, using ESBL- and non-ESBL-producing organisms, we assessed the translational value of this murine UTI model and humanized exposures for several frequently employed antimicrobial regimens for cUTI in humans. Levofloxacin displays poor clinical and microbiologic outcomes in the face of phenotypic resistance (9, 10). Similar to these clinical outcomes, data derived in the current study show a lack of efficacy in an organism defined as nonsusceptible when exposed to a humanized regimen. In an attempt to provide maximum in vivo exposures for cefepime, we utilized the 2-g q8h exposure as opposed to the lower 1-g dose that is often clinically utilized for cUTIs. Interestingly, despite this higher cefepime exposure, which initially demonstrated slight bacterial kill at 24 h, regrowth was noted during the following 24 h of therapy. These findings are reflective of clinical data in patients with ESBL-derived cUTIs (11). As expected, ertapenem was effective against both isolates, producing a large and sustained bacterial kill over 48 h. Our observations are consistent with the clinical and microbiologic outcomes reported for this compound in the setting of cUTIs (11–13).

The use of murine infection models during the anti-infective research and development process has been a standard practice since the 1950s (14). The selection of a model is dependent on the model's ability to mimic the disease pathogenesis observed in humans in relation to the antimicrobial's target therapeutic area (i.e., pneumonia, UTI, skin and soft tissue, etc.). To further enhance the translatability of these murine models to that of humans, the antimicrobial exposures in each species should be similar (humanized exposures). Since this murine model is intended to simulate a cUTI, a disease of the kidney/tissue, humanizing the plasma exposure is a more relevant target profile than that of urine. While it is expected that this plasma profile will result in sufficiently high urinary concentrations, additional studies may be undertaken to define the urinary profile of the compound of interest to ensure clinical applicability of the antimicrobial in the setting of both upper and lower urinary tract diseases.

To our knowledge, this is the first murine model of cUTI using completely humanized regimens to assess bacterial efficacy. In conclusion, the translatability of humanized antimicrobial exposures in murine cUTI models to human outcomes will be beneficial in determining optimal therapeutic options against these drug-resistant bacteria.

ACKNOWLEDGMENTS

We thank Jennifer Tabor-Rennie, Sara Robinson, Debora Santini, Elizabeth Cyr, Christina Sutherland, Kimelyn Greenwood, Islam Ghazi, Abrar Thabit, Kamilia Abdelraouf, and Mordechai Grupper from the Center for Anti-Infective Research and Development, Hartford, CT, for their assistance with conducting the study.

This study was internally funded by the Center for Anti-infective Research and Development.

FOOTNOTES

    • Received 27 June 2017.
    • Returned for modification 27 July 2017.
    • Accepted 22 August 2017.
    • Accepted manuscript posted online 28 August 2017.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Flores-Mireles AL,
    2. Walker JN,
    3. Caparon M,
    4. Hultgren SJ
    . 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol13:269–284. doi:10.1038/nrmicro3432.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Cantón R,
    2. Valverde A,
    3. Novais A,
    4. Baquero F,
    5. Coque T
    . 2007. Evolution and current situation of ESBL. Enferm Infecc Microbiol Clin25(Suppl 2):2–10. (In Spanish.)
    OpenUrl
  3. 3.↵
    1. Crandon JL,
    2. Nicolau DP
    . 2015. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother59:2688–2694. doi:10.1128/AAC.00033-15.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. DeRyke CA,
    2. Banevicius MA,
    3. Fan HW,
    4. Nicolau DP
    . 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother51:1481–1486. doi:10.1128/AAC.00752-06.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ghazi IM,
    2. Crandon JL,
    3. Lesho EP,
    4. McGann P,
    5. Nicolau DP
    . 2015. Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model. Antimicrob Agents Chemother59:7145–7147. doi:10.1128/AAC.00794-15.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
  7. 7.↵
    U.S. Food and Drug Administration. Microbiology review. Drug approval package: Avycaz. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000MicroR.pdf. Updated March 12, 2015. Accessed 26 January 2016.
  8. 8.↵
    1. Borgonovi M,
    2. Miossec C,
    3. Lowther J
    . 2007. The Efficacy of ceftazidime combined with NXL104, a novel β-lactamase inhibitor, in a mouse model of kidney infections induced by β-lactamase producing Enterobacteriaceae. Abstr Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany.
  9. 9.↵
    1. McGregor JC,
    2. Allen GP,
    3. Bearden DT
    . 2008. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther Clin Risk Manag4:843–853. doi:10.2147/TCRM.S3426.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Huntington JA,
    2. Sakoulas G,
    3. Umeh O,
    4. Cloutier DJ,
    5. Steenbergen JN,
    6. Bliss C,
    7. Goldstein EJ
    . 2016. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother71:2014–2021. doi:10.1093/jac/dkw053.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Seo YB,
    2. Lee J,
    3. Kim YK,
    4. Lee SS,
    5. Lee JA,
    6. Kim HY,
    7. Uh Y,
    8. Kim HS,
    9. Song W
    . 2017. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis17:404. doi:10.1186/s12879-017-2502-x.
    OpenUrlCrossRef
  12. 12.↵
    1. Sevgi DY,
    2. Gunduz A,
    3. Sahin AM,
    4. Derin O,
    5. Konuklar AS,
    6. Oncul A,
    7. Uzun N,
    8. Sonmez E
    . 2014. Ertapenem for the treatment of complicated urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria: a case series report. Dis Mol Med2:7–11. doi:10.5455/dmm.20140416054553.
    OpenUrlCrossRef
  13. 13.↵
    1. Fong JJ,
    2. Rosé L,
    3. Radigan EA
    . 2012. Clinical Outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing Gram-negative bacteria. Ann Pharmacother46:347–352. doi:10.1345/aph.1Q473.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Eagle H,
    2. Fleischman R,
    3. Musselman AD
    . 1950. The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms. Ann Intern Med33:544–571. doi:10.7326/0003-4819-33-3-544.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection
Marguerite L. Monogue, David P. Nicolau
Antimicrobial Agents and Chemotherapy Oct 2017, 61 (11) e01329-17; DOI: 10.1128/AAC.01329-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection
Marguerite L. Monogue, David P. Nicolau
Antimicrobial Agents and Chemotherapy Oct 2017, 61 (11) e01329-17; DOI: 10.1128/AAC.01329-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Escherichia coli Infections
urinary tract infections
Uropathogenic Escherichia coli
ESBL
Escherichia coli
urinary tract infection
cefepime
ertapenem
levofloxacin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596